MYM Nutraceuticals Inc.,(CSE:MYM) (CSE: MYM.CN)(MYM.CN) (the “Company” or “MYM”) is pleased to announce it as engaged well-known tourism and recreational expert, Sylvain Audet, to develop the concept of the CannaCentre in Weedon, QC. The CannaCentre is associated with the Company’s 1.5 million square foot medical cannabis greenhouse complex currently under construction in Weedon, Quebec. The CannaCentre will host a research centre, a training facility, an auditorium for cultural and scientific activities, a hotel, a restaurant, a medical cannabis interpretation centre and a medical clinic.
Mr. Audet will work in close collaboration with the Sherbrooke Historical Society to develop the concept of the medical cannabis museum as part of the CannaCentre. Mr. Audet is tasked with identifying the primary, indirect and complementary clientele targets, to suggest services and activities complementary to the project’s infrastructure and evaluate the profitability of the overall project.
“The addition of Sylvain Audet provides the project with the expertise for a harmonious tourism and cultural development,” said Rob Gietl, CEO of MYM. “Mr. Audet’s expertise will allow the region to offer a world-class tourism product that is in line with the needs of the local population.”
Mr. Audet’s experience includes positions with high-end hotels and resorts, regional organizations promoting tourism and ski resorts in the Eastern Townships. Mr. Audet has more than twenty-five years-experience as a recreational tourism consultant for several companies and regional organizations in Canada. He has acquired extensive expertise in tourism brand development, financial benchmarking analysis, marketing research and business plan development in several recreational tourism fields.
Mr. Audet is currently an instructor at the Université du Quebec à Montreal (UQAM) in the institution’s Hospitality and Tourism Management program. Mr. Audet holds a Master of Business Administration (MBA) from Université Laval(Quebec City) and a Bachelor of Business Administration (BAA) in Management and Tourism Intervention from UQAM. Mr. Audet is currently working on a PhD in Business Administration (DBA) at the Heriot-Watt University’s Edinburgh Business School (Scotland).
About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Quebec that are anticipated to have over 1.5 million square feet of production space. MYM is also a shareholder in two additional cannabis production projects in Australia and Colombia. The “Northern Rivers Project” in New South Wales, Australia is expected to have 1.2 million square feet of cannabis production space. In Colombia, MYM partner, Colombia Organica, currently hold a seed to sale license for low THC cannabis and are in the licensing process for the cultivation and production of high THC cannabis extracts. Plans are underway for MYM and Colombia Organica to build a cannabis production facility in the region. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
Keep up to date with MYM on our social media channels:
This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on http://www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.